Pantoprazole: A new proton pump inhibitor in the management of upper gastrointestinal disease

Drugs of Today

Volumn 35, Issue 10, 1999, Pages 773-808

  Bardhan, K D ^a  

^a Rotherham NHS Foundation Trust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; ANTIBIOTIC AGENT; BENZIMIDAZOLE DERIVATIVE; BISMUTH; CIMETIDINE; CLARITHROMYCIN; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; TINIDAZOLE;

ANTIBIOTIC RESISTANCE; COST BENEFIT ANALYSIS; DIARRHEA; DRUG INDUCED DISEASE; DUODENUM ULCER; ESOPHAGITIS; GASTRITIS; GASTROESOPHAGEAL REFLUX; HEADACHE; HELICOBACTER PYLORI; HUMAN; REVIEW; STOMACH ULCER; TREATMENT OUTCOME; ULCER HEALING; VERTIGO; ZOLLINGER ELLISON SYNDROME;

EID: 0033382692     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1999.35.10.561696     Document Type: Review

References (209)

1. Classen, M., Delle Fave, G. Management of acid related diseases: Focus on pantoprazole. Aliment Pharmacol Ther 1994, 8 (Suppl. 1): 1-2.
2. Fitton, A., Wiseman, L. Pantoprazole: A review of its pharmacological properties and therapeutic use in acid related disorders. Drugs 1996, 51: 60-82.
3. McTavish, D., Buckley, M.T., Heel, C. Omeprazole: An updated review of its pharmacology and therapeutic use in acid related disorders. Drugs 1991, 42: 138-70.
4. Spencer, C.M., Faulds, D. Lansoprazole: A reappraisal of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid related disorders. Drugs 1994, 48: 404-30.
5. Burget, D.W., Chiverton, S.G., Hunt, R.H. Is there an optimal degree of acid suppression for healing of duodenal ulcer? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990, 99: 345-51.
6. Howden, C.W., Hunt, R.H. The relationship between suppression of acidity and gastric ulcer healing rate. Aliment Pharmacol Ther 1990, 4: 25-33.
7. Bell, N.J., Burget, D., Howden, C.W., Wilkinson, J., Hunt, R.H. Appropriate acid suppression for the management of gastroesophageal reflux disease. Digestion 1992, 51 (Suppl. 1): 56-67.
8. Mohamed, A.H., Hunt, R.H. The rationale of acid suppression in the treatment of acid related diseases. Aliment Pharmacol Ther 1994, 8 (Suppl. 1): 3-11.
9. 2-receptor antagonists. Eur J Gastroenterol Hepatol 1992, 4: 147-63.
10. Poynard, T., Lemaire, M., Agostini, H. Metaanalysis of randomised clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 1995, 7: 661-5.
11. Bardhan, K.D., Hollander, D., Festen, H.P.M., Bianchi-Poffo, G. Changing strategies for chronic peptic ulcer disease. Gastroenterol Int 1990, 1: 3-21.
12. Singh, P., Colin-Jones, D. Modern management of peptic ulcer disease. Br J Hosp Med 1992, 47: 44-50.
13. Penston, J.G., Wormsley, K.G. Nine year maintenance treatment with ranitidine for patients with duodenal ulcer. Aliment Pharmacol Ther 1992, 6: 629-45.
14. Bardhan, K.D. Is there any acid peptic disease that is refractory to proton pump inhibitors? Aliment Pharmacol Ther 1993, 1 (Suppl. 1): 13-24.
15. Schiller, K.F.R., Axon, A.T.R., Carr-Locke, D.L. Duodenal ulcer after healing with omeprazole or cimetidine: A multicentre study in the UK. Gut 1989, 30: A1490.
16. Lauritsen, K., Anderson, B.N., Laursen, L.S. et al. Omeprazole 20 mg three days a week and 10 mg daily in prevention of duodenal ulcer relapse. Gastroenterology 1991, 100: 663-9.
17. Oliveri, P., Marcon, V., Crestini, B. et al. Six months omeprazole 20 mg daily, 20 mg every other day or 40 mg at weekends in duodenal ulcer patients: A multicentre, prospective comparative study. Digestion 1995, 56: 181-6.
18. Bardhan, K.D. Omeprazole in the treatment of gastroesophageal reflux disease. In: Advances in Drug Therapy of Gastroesophageal Reflux Disease: Frontiers in Gastrointestinal Research. Scarpignato, C. (Ed.). Karger: Basel 1992, 20: 246-306.
19. Sontag, S.J. Rolling review: Gastroesophageal reflux disease. Aliment Pharmacol Ther 1993, 7: 293-312.
20. Lambert, R. Review article: Current practice and future perspectives in the management of reflux disease. Aliment Pharmacol Ther 1997, 11: 651-62.
21. Sandmark, S. Omeprazole or ranitidine in the treatment of reflux esophagitis. Scand J Gastroenterol 1988, 23: 625-32.
22. Hetzel, D.J., Dent, J., Reed, V.D. et al. Healing and relapse of severe peptic stricture after treatment with omeprazole. Gastroenterology 1988, 95: 903-12.
23. Bardhan, K.D., Cherian, P., Vaishnavi, A. et al. Erosive esophagitis: Outcome of repeated long term treatment with low dose omeprazole 10 mg or placebo. Gastroenterology 1995, 108: A53.
24. Laurent, J., Cassan, P., Rey, J.F., Helbert, T., Arnould, B. Efficacy of omeprazole 20 mg followed by maintenance treatment with omeprazole 10 mg for the relief and prophylaxis against recurrence of GERD symptoms in patients with low grade esophagitis. Gastroenterology 1995, 108: A145.
25. Vigneri, S., Termini, R., Leandro, G. et al. A comparison of five maintenance therapies for reflux esophagitis. New Engl J Med 1995, 333: 1106-10.
26. Dent, J., Yeomans, N.D.Y., Mackinnon, M. et al. Omeprazole vs ranitidine for prevention of relapse in reflux esophagitis: A controlled double blind trial of their efficacy and safety. Gut 1994, 35: 590-8.
27. Hallerbäck, B., Edwin, B., Glise, H., Havu, N., Lyrenäs, E., Lundberg, K. Omeprazole or ranitidine in long term treatment of reflux esophagitis. The Scandanavian Clinics for United Research Group. Gastroenterology 1994, 107: 1305-11.
28. Robinson, M., Lanza, F., Avner, D., Haber, M. Effective maintenance treatment of reflux esophagitis with low dose lansoprazole. A randomised double blind placebo controlled trial. Ann Intern Med 1996, 124: 859-67.
29. Bate, C.M., Booth, S.N., Crowe, J.P. et al. Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux esophagitis. Solo Investigator Group. Gut 1995, 34: 492-8.
30. Hattlebäck, J.G., Berstad, A. Prognostic factors for relapse of reflux esophagitis and symptoms during 12 months of therapy with lansoprazole. Aliment Pharmacol Ther 1997, 11: 1093-9.
31. Gough, A.L., Long, R.G., Cooper, B.T., Fosters, C.F., Garrett, A.D., Langworthy, C.H. Lansoprazole vs ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther 1996, 10: 529-39.
32. Baldi, F., Bardhan, K.D., Borman, B.C. et al. Lansoprazole maintains healing in patients with reflux esophagitis. The European Lansoprazole Study Group. Gastroenterology 1996, 100: A55.
33. Poynard, T. Relapse of patients after healing of esophagitis, a prospective study of alginates as self care treatment for 6 months. The French Cooperative Study Group. Aliment Pharmacol Ther 1993, 7: 385-92.
34. Bardhan, K.D., Müller-Lissner, S., Bigard, M.A. et al. Symptomatic gastroesophageal reflux disease, intermittent treatment with omperazole and ranitidine as a strategy for management. The European Study Group. Gastroenterology 1997, 112: A65.
35. Bardhan, K.D. Duodenal ulcer and gastroesophageal reflux disease today: Long term therapy - A sideways glance. Yale J Biol Med 1996, 69: 211-24.
36. Bardhan, K.D. Reflux rising - A burning issue. A personal overview of treatment. Res Clin Forums 1998, 2: 27-32.
37. Londong, W. Effect of pantoprazole on 24hr intragastric pH and serum gastrin in humans. Aliment Pharmacol Ther 1994, 8 (Suppl. 1): 39-46.
38. Reill, L., Erhardt, F., Fischer, R., Londong, W. Intragastric pH and serum gastrin after one week treatment with pantoprazole, ranitidine or placebo in man. Gastroenterology 1993, 104: A177.
39. Hartmann, M., Theiss, U., Huber, R. et al. Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Aliment Pharmacol Ther 1996, 10: 359-66.
40. Koop, H., Kuly, S., Flug, M., Rose, K., Fischer, R., Arnold, R. 24hr intragastric pH and 24hr gastrin profiles during therapy with different doses of the new proton pump inhibitor pantoprazole. Gut 1994, 15 (Suppl. 4): A1066.
41. Brunner, G., Danz-Neef, H., Athmann, C., Samayoa, N. Comparison of pantoprazole (40 mg sid) versus omeprazole (40 mg sid) on intragastric pH and serum gastrin in healthy volunteers. Gastroenterology 1997, 112: A78.
42. Dammann, H.G., Burkhardt, S. Pantoprazole versus omeprazole: Influence on meal-stimulated gastric acid secretion. Eur Gastroenterol Hepatol 1999, 11: 1277-82.
43. Müssig, S., Witzel, L., Lühmann, R., Schneider, A. Morning and evening administration of pantoprazole: A study to compare the effect on 24-hour intragastric pH. Eur J Gastroenterol Hepatol 1997, 9: 599-602.
44. Reill, L., Erhardt, F., Heinzerling, H., Huber, R., Londong, W. Dose-response of pantoprazole 20, 40, and 80 mg on 24 hour intragastric pH, serum pantoprazole and serum gastrin in man. Gastroenterology 1994, 106: A165.
45. Fuder, H., Ehrlich, A., Wieckhorst, G., Lücker, P.W., Cain, C.R. Pantoprazole once daily versus twice daily: A pH-metry study. Gastroenterology 1997, 112: A120.
46. Straathof, J.W.A., Gielkens, H.A.J., Wurst, W. et al. Pentagastrin enhances the effect of intravenous pantoprazole. Gastroenterology 1997, 112: A299.
47. Pisegna, J.F., Asvar, C.A., Lew, E.A. et al. Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: A dose ranging study. Gastroenterology 1998, 114: A34.
48. Pisegna, J.R., Huang, M., Asvar, C. et al. Inhibition of pentagastrin-induced gastric acid hypersecretion by single dose intravenous famotidine and placebo in healthy subjects. Gastroenterology 1998, 114: A259.
49. Hartmann, M., Ehrlich, A., Fuder, H. et al. Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole. Aliment Pharmacol Ther 1998, 12: 1027-32.
50. van Rensburg, C.J., Thorpe, A., Warren, B. et al. Intragastric pH in patients with bleeding peptic ulceration during pantoprazole infusion of 8 mg/hour. Gastroenterology 1997, 112: A321.
51. 2 antagonists in acute upper gastrointestinal haemorrhage. New Engl J Med 1985, 313: 660-6.
52. Daneshmend, T.K., Hawkey, C.J., Logan, R.A.F., Long, R.A., Walt, R.P. Omeprazole versus placebo for acute upper gastrointestinal bleeding: Randomised double blind controlled trial. Br Med J 1992, 304: 143-7.
53. Schaffalitzky, O.B., Muckadell, D.E., Havelund, T., Harling, H., Boesby, S., Snell, P. Effect of omeprazole on the outcome of endoscopically treated bleeding peptic ulcer. Scand J Gastroenterol 1997, 32: 320-7.
54. Hasselgren, G., Lind, T., Lundell, L., Aadland, E., Efskind, P., Falk, A. Continuous intravenous infusion of omeprazole in elderly patients with peptic ulcer bleeding. Scand J Gastroenterol 1997, 32: 328-33.
55. Khuroo, M.S., Yattoo, G.N., Javid, G., Khan, B.A., Shah, A.A., Gulzar, G.M. A comparison of omeprazole and placebo for bleeding peptic ulcer. New Engl J Med 1997, 336: 1054-8.
56. Metz, D.C., Lew, E., Forsmark, C.E., Bochenek, W., Beg, M., Pisegna, J. Intravenous pantoprazole rapidly and effectively controls acid output in patients with Zollinger-Ellison syndrome. Gastroenterology 1998, 114: A226.
57. McColl, K.E.L., Nujumi, A.M., Dorrian, C.A., MacDonald, A.M., Fullarton, G.M., Harwood, J. Helicobacter pylori and hypergastrinaemia during proton pump inhibitor therapy. Scand J Gastroenterol 1992, 27: 93-8.
58. Labenz, J., Tillenburg, B., Peitz, U. et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996, 110: 725-32.
59. Bercik, P., Verdü, E.F., Armstrong, D. et al. Apparent increase in acid output during omeprazole after cure of H. pylori infection. Gastroenterology 1997, 112: A70.
60. Bader, J.P., Delchier, J.C. Clinical efficacy of pantoprazole compared with ranitidine. Aliment Pharmacol Ther 1994, 8 (Suppl. 1): 47-52.
61. Dibildox, M., Rose, K., Tomás-Pons, J., Fischer, R., Gallo, S. Superiority of pantoprazole over ranitidine in the treatment of duodenal ulcer. Mexican clinical experience. The Mexican Pantoprazole in Duodenal Ulcer Study Group. Rev Gastroenterol Mex 1996, 61: 193-8.
62. Baccaro, J.C., Besasso, H., Dávolos, J.R. et al. Pantoprazole is superior to ranitidine in the treatment of florid duodenal ulcer. Preliminary results of a pantoprazole multicenter study in Argentina. Gastroenterology 1996, 110: A54.
63. Castro, L.P., Lyra, L.G.C., Malafaia, O. et al. Pantoprazole achieves better healing than ranitidine in the treatment of acute duodenal ulcer. Pantoprazole multicentre study in Brazil. Gastroenterology 1996, 110: A78.
64. Hahn, E.G., Scholten, T. Efficacy and tolerability of pantoprazole versus ranitidine and famotidine in patients with acute duodenal ulcers: Multicentre, open, randomised, controlled studies. In: International Clinical Practice Series. The German Pantoprazole Phase IV Programme. Domschke, W. (Ed.). Wells Medical: Kent 1997, 13-8.
65. Bosseckert, H. Efficacy and tolerability of pantoprazole versus ranitidine in patients with acute gastric ulcers: Multicentre, open, randomised, controlled study. In: International Clinical Practice Series. Domschke, W. (Ed.). The German pantoprazole phase IV programme. Kent: Wells Medical 1997, 19-22.
66. Scheirle, A., Fric, P., Juhász, Z. et al. Clinical superiority of pantoprazole vs ranitidine in patients with florid dudoenal ulcers. Gastroenterology 1997, 112: A281.
67. Rohner, H.G., Tangerding, G., Maier, C. Pain relief with pantoprazole or ranitidine in symptomatic patients with acute duodenal ulcer: A multicenter study. Gastroenterology 1998, 114: A270.
68. Rodrigo, M., Sáinz, R., Hernández, J.M. et al. Clinical efficacy and safety of pantoprazole versus ranitidine in patients with acute duodenal ulcer. Spanish multicentre study. Gastroenterology 1998, 114: A269.
69. Schepp, W., Classen, M. Pantoprazole and ranitidine in the treatment of acute duodenal ulcer. A multicentre study. Scand J Gastroenterol 1995, 30: 511-14.
70. van Rensburg, C.J., van Eeden, P.J., Marks, I.N. et al. Improved duodenal ulcer healing with pantoprazole compared to ranitidine: A multicentre study. Eur J Gastroenterol Hepatol 1994, 6: 739-43.
71. Judmaier, G., Koelz, H.R. Comparison of pantoprazole and ranitidine in the treatment of acute duodenal ulcer. The Pantoprazole-Duodenal Ulcer-Study Group. Aliment Pharmacol Ther 1994, 8: 81-6.
72. Cremer, M., Lambert, R., Lamers, C.B.H.W., Delle Fave, G., Maier, C. A double-blind study of pantoprazole and ranitidine in treatment of acute duodenal ulcer. A multicenter trial. The European Pantoprazole Study Group. Dig Dis Sei 1995, 40: 1360-4.
73. Beker, J.A., Bianchi Porro, G., Bigard, M.A. et al. Double-blind comparison of pantoprazole and omeprazole for the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 1995, 7: 407-10.
74. Rehner, M., Rohner, H.G., Schepp, W. Comparison of pantoprazole versus omeprazole in the treatment of acute duodenal ulceration - A multicentre study. Aliment Pharmacol Ther 1995, 9: 411-6.
75. Denis, J., Belin, J. Comparison à 28 jours d'un traitement de deux semaines et d'un traitement de quatre semaines par le pantoprazole 40mg/jour chez des patients présentant un ulcère duodénal. Méd Chir Dig 1998, 27: 211-6.
76. Bardhan, K.D., Dobrilla, G. Refractory duodenal ulcer. In: Non-responders in Gastroenterology. Dobrilla, G., Bardhan, K.D., Steele, A. (Eds.). Raven Press: New York 1991, 71-110.
77. Savarino, V., Mela, G.S., Zentilin, P. et al. Comparison of 24-h control of gastric acidity by three different dosages of pantoprazole in patients with duodenal ulcer. Aliment Pharmacol Ther 1998, 12: 1241-7.
78. Editorial. Cimetidine for ever and ever. Br Med J 1978, 1: 1435-6.
79. Witzel, L., Gütz, H., Hüttemann, W., Schepp, W. Pantoprazole versus omeprazole in the treatment of acute gastric ulcers. Aliment Pharmacol Ther 1995, 9: 19-24.
80. Hotz, J., Plein, K., Schönekäs, H., Rose, K. Pantoprazole is superior to ranitidine in the treatment of acute gastric ulcer. Scand J Gastroenterol 1995, 30: 111-5.
81. Florent, Ch., Forestier, S., Joubert-Collin, M. Lansoprazole versus omeprazole: Efficacy and safety in acute gastric ulcer. Gastroenterology 1994, 104: A80.
82. Arendt, R., Porst, H., Rohner, H.G., Mönch, H., Bethke, T., Schneider, A. Peptic ulcer recurrence following treatment with pantoprazole or ranitidine. Gastroenterology 1995, 106: A48.
83. Penston, J.G. Review article: Helicobacter pylori eradication - Understandable caution but no excuse for inertia. Aliment Pharmacol Ther 1994, 8: 369-89.
84. Penston, J.G. Review article: Clinical aspects of Helicobacter pylori eradication therapy in peptic ulcer disease. Aliment Pharmacol Ther 1996, 10: 469-86.
85. Penston, J.G., McColl, K.E. Eradication of Helicobacter pylori: An objective assessment of current therapies. Br J Clin Pharmacol 1997, 43: 223-43.
86. Proceedings of the American Digestive Health Foundation International Update Conference on Helicobacter pylori. McLean, Virginia. USA, February 13-16, 1997. Gastroenterology 1997, 113: S1-169.
87. Management of Helicobacter pylori infection. Proceedings from a 3rd roundtable meeting. Ascot, England, 27-28 June, 1996. Aliment Pharmacol Ther 1997, 11 (Suppl.): 1-109.
88. Current European concepts in the management of Helicobacter pylori infection. Maastricht Consensus Report. European Helicobacter Pylori Study Group. Gut 1997, 41: 8-13.
89. Louw, J.A., Marks, I.N., van Rensburg, C.J., Jaskiewicz, K., Theron, I., Bethke, T. The effect of pantoprazole as monotherapy and in combination with amoxicillin, on gastric H. pylori status, in duodenal ulcer subjects. Gut 1994, 35 (Suppl. 2): S63.
90. Dollinger, M.M., Kroesen, M., Dollinger, H.C. Short term therapy of Helicobacter pylori gastritis. Gut 1996, 39 (Suppl. 3): 813.
91. Adamek, R.J., Bethke, T. Cure of Helicobacter pylori infection and healing of duodenal ulcer: Comparison of pantoprazole-based one-week modified triple therapy versus two-week dual therapy. The International Pantoprazole HP Study Group. Am J Gastroenterol 1998, 93: 1919-24.
92. Schütze, K., Hentschel, E. Dual therapy with pantoprazole and clarithromycin for eradication of Helicobacter pylori. Gastroenterology 1997, 112: A284.
93. Ratajczak, T., Ratajczak, S., Rabinski, J. Pantoprazole and amoxicillin combined therapy of duodenal ulcer. Gastroenterol Pol 1997, 4: 61-4.
94. Svoboda, P., Kantorová, I., Ochmann, J., Doubek, J., Kozumplik, L., Marsová, J. Pantoprazole-based dual and triple therapy for the eradication of Helicobacter pylori infection: A randomized controlled trial. Hepato-Gastroenterol 1997, 44: 886-90.
95. Seelis, R.E.A., Dohmen, W. Six-day eradication treatment of Helicobacter pylori infection in a non-hospital practice. Dtsch Med Wochenschr 1998, 123: 103-8.
96. Dehesa, M., Larisch, J., Dibildox, M. et al. Comparison of two schedules based on pantoprazole for eradication of Helicobacter pylori in patients with active duodenal ulcer. Rev Gastroenterol Mex 1998, 63: 66-71.
97. Witteman, E.M., Hazenberg, B.P., Haek, P.W.E. et al. Comparison of pantoprazole-based dual and triple therapies for H. pylori eradication: Effects on symptoms in nonulcer dyspepsia patients. Gut 1997, 41 (Suppl. 3): A199.
98. Adamek, R.J., Szymanski, C., Pfaffenbach, B., Offerkuch, W., Ricken, D., Wegener, M. Short-term triple therapy with pantoprazole, clarithromycin and metronidazole for the healing of Helicobacter pylori infection. Dtsch Med Wochenschr 1995, 120: 358-60.
99. Labenz, J., Peitz, U., Tillenburg, B., Becker, T., Borsch, G., Stolte, M. Short term triple therapy with pantoprazole, clarithromycin and metronidazole for eradication of Helicobacter pylori. Leber Magen Darm 1995, 25: 122-7.
100. Labenz, J., Tillenburg, B., Weismüller, J., Lütke, A., Stolte, M. Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxicillin for cure of Helicobacter infection in patients with duodenal ulcer. Aliment Pharmacol Ther 1997, 11: 95-100.
101. Adamek, R.J., Szymanski, Ch., Pfaffenbach, B. Pantoprazole suppresses Helicobacter pylori without affecting cure. Helicobacter 1999, 4: in press.
102. Adamek, R.J., Pfaffenbach, B., Szymanski, C. Cure of H. pylori infection using a 7 day triple therapy combining pantoprazole with two antibiotics. Helicobacter 1998, 1: 206-11.
103. Adamek, R.J., Szymanski, C., Pfaffenbach, B. Pantoprazole versus omeprazole in one-week low-dose triple therapy for cure of H. pylori infection. Am J Gastroenterol 1997, 92: 1949-50.
104. Frevel, M., Daake, H., Janisch, H.D. et al. Pantoprazole plus clarithromycin and metronidazole versus pantoprazole plus clarithromycin and amoxicillin for therapy of H. pylori infections. Gastroenterology 1997, 112: A119.
105. Stölzle, L., Klann, H., Topf, G., Seib, H.J. Ten day treatment with pantoprazole, amoxicillin and metronidazole for cure of Helicobacter pylori infection. Gastroenterology 1997, 112: A299.
106. Witzel, L., Leder, K. Cure of Helicobacter pylori in duodenal ulcer disease with triple therapy consisting of pantoprazole, clarithromycin and metronidazole. Gastroenterology 1997, 112: A332.
107. Triantafyllou, G., Raptis, N., Petraki, C. et al. A short term (weekly) low cost triple therapy (pantoprazole-tetracycline metronidazole) for H. pylori eradication and cure of peptic ulcer disease. Preliminary positive results. Gastroenterology 1997, 112: A1403.
108. Lamouliatte, H., Samoyeau, R., de Mascarel, A., Megraud, F. Double vs. single dose of pantoprazole in combination with clarithromycin and amoxicillin for 7 days, in eradication of Helicobacter pylori in patients with nonulcer dyspepsia. Aliment Pharmacol Ther 1999, 13: 1523-30.
109. Dammann, H.G., Fölsch, U.P., Hann, E.G. et al. Eradication of H. pylori with pantoprazole, clarithromycin, and metronidazole in duodenal ulcer patients. A head-to-head comparison between two regimens of different duration. Helicobacter 1999, in press.
110. Luna, P., del Castillo, G., Farias, R. et al. Efficacy and tolerability of a seven-day triple scheme with pantoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori. Gastroenterology 1997, 112: A202.
111. Ellenrieder, V., Fensterer, H., Waurick, M., Adler, G., Glasbrenner, B. Influence of clarithromycin dosage on pantoprazole combined triple therapy for eradication of Helicobacter pylori. Aliment Pharmacol Ther 1998, 12: 613-8.
112. Rodriguez Tellez, M., Valenzuela, M., Martin Ruiz, M., Carmona, I., Quintero, M.D., Lavin, I. Effect of clarithromycin, amoxicillin and pantoprazole (CAP) in duodenal ulcer healing and H. pylori eradication. Preliminary report. Gut 1997, 41 (Suppl. 3): A208.
113. Dajani, A., Awad, S., Ukabam, S. et al. One-week triple regime therapy consisting of pantoprazole, amoxicillin and clarithromycin for cure of Helicobacter pylori-associated upper gastrointestinal diseases. Digestion 1999, 60: 298-304.
114. Dominguez-Martin, A., Dominguez-Muñoz, A., Muńoz, S., Alonso, J.B., Gonzalez, M.D. Efficacy of six days triple therapy with pantoprazole plus clarithromycin and amoxicillin versus omeprazole plus clarithromycin and amoxicillin for H. pylori eradication. Gastroenterology 1998, 114: A107.
115. Dehesa, M., Larisch, J., Dibildox, M. et al. Comparison of two pantoprazole-based regimens for eradication of Helicobacter pylori in patients with active duodenal ulcer. Rev Gastroenterol Mexico 1998, 63: 66-71.
116. Wurzer, H., Kratochvil, P., Stupnicki, T. Eradication of Helicobacter pylori by means of a low-dose one-week triple therapy containing pantoprazole, clarithromycin and metronidazole. Gastroenterology 1998, 114: A335.
117. Marais, A., Monteiro, L., Lamouliatte, H., Samoyeau, R., Mégraud, F. Cag negative status of Helicobacter pylori is a risk factor for failure of PPI based triple therapies in non-ulcer dyspepsia. Gastroenterology 1998, 114: A214.
118. Glaser, J., Hein, J., Daikeler, R. et al. Short-term triple therapy with pantoprazole, amoxicillin and metronidazole in Helicobacter pylori infection. Med Klin 1998, 93: 65-9.
119. Pilotto, A., Leandro, G., Franceschi, M. et al. Rapid improvement of symptomatology with pantoprazole, amoxycillin and metronidazole in Helicobacter pylori-positive duodenal ulcer patients. Hepatogastroenterology 1999, 46: 245-51.
120. Willkomm, G., Birkner, B., Fink, R., Kunze, P., Saitner, M., Schepp, W. Pantoprazole plus azithromycin and metronidazole for cure of Helicobacter pylori infection. Gastroenterology 1998, 114: A332.
121. Bardhan, K.D., Dillon, J., Axon, A.T.R. et al. Pantoprazole-based triple therapy for H. pylori eradication: A comparison of pantoprazole once versus twice daily. Aliment Pharmacol Ther 1999, in press.
122. Bardhan, K.D., Morton, D., Slater, D.N. et al. Pantoprazole-based 10-day triple therapy is effective in H. pylori eradication. Aliment Pharmacol Ther 1998, 12: 185-9.
123. Pazzi, P., Scagliarini, R., Gamberini, S., Matarese, V., Rizzo, C., Guilini, S. Short-term low-dose pantoprazole-based triple therapy for cure of Helicobacter pylori infection in duodenal ulcer patients. Aliment Pharmacol Ther 1998, 12: 731-4.
124. Louw, J.A., van Rensburg, C.J., Hanslo, D., Grundling, H.D., Girdwood, A.M., Marks, I.N. Two-week course of pantoprazole combined with 1 week of amoxicillin and clarithromycin is effective in Helicobacter pylori eradication and duodenal ulcer healing. Aliment Pharmacol Ther 1998, 12: 545-50.
125. Lind, T., Veldhuyzen van Zanten, S., Unge, P. et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials. The Mach 1 study. Helicobacter 1996, 1: 138-44.
126. Misiewicz, J.J., Harris, A.W., Bardhan, K.D. et al. One week triple therapy for Helicobacter pylori: A multicentre comparative study. Gut 1997, 41: 735-40.
127. Dammann, H.G., Fölsch, U.R., Kirchner, T., Hahn, E.G. A three year follow-up study in patients with endoscopically proven healed peptic ulcer and eradicated H. pylori. Gastroenterology 1998, 114: A97.
128. George, L.L., Borody, T.J., Andrews, P. et al. Cure of duodenal ulcer after eradication of Helicobacter pylori. Med J Aust 1990, 154: 145-9.
129. Forbes, G.M., Glaser, M.E., Cullen, D.J. et al. Duodenal ulcer treated with Helicobacter pylori eradication: Seven-year follow-up. Lancet 1994, 343: 258-60.
130. van der Hulst, R.W.M., Rauws, E.A.J. et al. Prevention of ulcer recurrence after eradication of Helicobacter pylori: A prospective long-term follow-up study. Gastroenterology 1997, 113: 1082-6.
131. Bell, G.D., Powell, K.U., Burridge, S.M. et al. Reinfection or recrudescence after apparently successful eradication of Helicobacter infection and implications for treatment of patients with duodenal ulcer disease. Q J Med 1993, 86: A109.
132. Harris, A.W., Gummett, P.A., Misiewicz, J.J., Baron, J.H. The effect of eradication of Helicobacter pylori on gastric acid output in patients with duodenal ulcer. Gastroenterology 1995, 108: A109.
133. Kahm, O.N., Logan, R.P.H. The epidemiology of Helicobacter pylori antimicrobial resistance: Preliminary findings of a national survey. Gut 1995, 37 (Suppl. 2): A6.
134. Harries, A.D., Stewart, M., Deegan, K.M. et al. Helicobacter pylori in Malawi, Central Africa. J Infect 1992, 24: 269-76.
135. Glupzinski, Y., Goutier, S., VanDen Borre, C., Bulzier, J.P., Burette, A. Surveillance of Helicobacter pylori resistance to antimicrobial agents in Belgium from 1989 to 1994. Gut 1995, 37 (Suppl. 1): A56.
136. Xia, H.X., Keane, C.T., O'Morain, C.A. A five year survey of metronidazole and clarithromycin resistance in clinical isolates of Helicobacter pylori. Gut 1996, 39 (Suppl. 2): A6.
137. De Koster, E., Cozzoli, A., Jonas, C. et al. Six years resistance of Helicobacter pylori to macrolides and irnidazoles. Gut 1996, 39 (Suppl. 2): A5.
138. Morton, D., Bardhan, K.D. A six-year assessment of tinidazo/e, metronidazole, clarythromycin, tetracycline and amoxicillin resistance in Helicobacter pylori clinical isolates -A rising tide of antibiotic resistance. Gut 1998, 42 (Suppl.): A78.
139. Morton, D., Segal, I., Bardhan, K.D. Helicobacter pylori antimicrobial susceptibilities - A tale of two cities. Gastroenterology 1998, 114: A234.
140. Lopez-Brea, M., Domingo, D., Sanchez, I., Hernandez, J.M., Villa, H., Alarcon, T. Metronidazole and clarithromycin susceptibility amongst H. pylori clinical isolates from different Spanish regions. Gut 1996, 29 (Suppl. 2): A37.
141. Fennerty, M.B. Should we abandon metronidazole-containing Helicobacter pylori treatment regimens? The clinical relevance of metronidzole resistance. Am J Gastroenterol 1998, 93: 2-3.
142. Bazzoli, F., Zagari, R.M., Fossi, S. et al. Short-term low dose triple therapy for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1994, 6: 773-7.
143. Seelis, R., Dohmen, W. Eradication of Helicobacter pylori: Synergistic effect of azithromycin and tinidazole but not amoxicillin. Gut 1997, 41 (Suppl. 3): A208.
144. De Boer, S.Y., Meeberg, P.C., Siem, T.H., De Boer, W.A. Comparison of seven and four day pantoprazole based quadruple therapy as a routine treatment for Helicobacter pylori infection. Gastroenterology 1999, 116: A145.
145. De Boer, W.A., Driessen, V.M.M., Jansz, A.R., Tytgat, G.N.J. Effect of acid supression on efficacy of treatment for Helicobacter infection. Lancet 1995, 345: 817-20.
146. De Boer, W.A., Tytgat, G.N.J. Ninety percent cure: Which anti-Helicobacter therapy can achieve this treatment goal? Am J Gastroenterol 1995, 90: 1381-2.
147. Harris, A.W., Misiewicz, J.J. Eradication of Helicobacter pylori. Ballieres Clin Gastroenterol 1995, 9: 583-613.
148. De Boer, W.A., Rudd, J.X.M., Van Etten, M.D. et al. Four day lansoprazole quadruple therapy: A highly effective cure for Helicobacter infection. Am J Gastroenterol 1996, 91: 1778-82.
149. Dammann, H.G., von Kleist, D.H. Efficacy and tolerability of pantoprazole versus ranitidine and famotidine in patients with gastrooesophageal reflux disease: Multicentre, open, randomised, controlled studies. In: International Clinical Practice Series. The German Pantoprazole Phase IV Programme. Domschke, W. (Ed.). Wells Medical: Kent 1997, 23-9.
150. Duvnjak, M., Simicevic, V.N., Supanc, V., Troskot, B., Pavic, T., Hrabar, D. Efficacy of pantoprazole in gastroesophageal reflux disease. A comparison with ranitidine. Digestion 1998, 59 (Suppl. 3): 583.
151. Gallo, S., Dibildox, M., Moguel, A. et al. Clinical superiority of pantoprazole over ranitidine in the treatment of reflux esophagitis grade II and III. A prospective, double-blind, double-placebo study. Mexican clinical experience. The Mexican Pantoprazole Study Group. Rev Gastroenterol Mex 1998, 63: 11-6.
152. Koop, H., Schepp, W., Dammann, H.G., Schneider, A., Lühmann, R., Classen, M. Comparative trial of pantoprazole and ranitidine in the treatment of reflux esophagitis: Results of a German multicentre study. J Clin Gastroenterol 1995, 20: 192-5.
153. Audigier, J.C., Marek, L., Belin, J. An epidemiological investigation in patients with clinical symptoms of gastroesophageal reflux disease in general medical practice and a pragmatic study on safety and efficacy of pantoprazole in case of oesophagitis endoscopically proven. Gastroenterology 1998, 114: A61.
154. van Zyl, J.H., Grundling, H., van Rensburg, C.J. et al. Efficacy and tolerability of 20 mg pantoprazole versus 300 mg ranitidine in patients with mild reflux-oesophagitis: A randomised, double-blind, parallel, and multicenter study. Eur J Gastroenterol Hepatol 1999, in press.
155. Dettmer, A., Vogt, R., Sielaff, F., Lühmann, R., Schneider, A., Fischer, R. Pantoprazole 20 mg is effective for relief of symptoms and healing of lesions in mild reflux oesophagitis. Aliment Pharmacol Ther 1998, 12: 865-72.
156. Ramirez-Barba, E.J., Dibildox, M., Bernai, F. et al. and the Mexican Pantoprazole Study Group. Low-dose pantoprazole (20 mg) is effective for treatment of mild reflux oesophagitis. Clin Drug Invest 1999, 18: in press.
157. Bardhan, K.D., van Rensburg, C. Comparison of pantoprazole (panto) 20 mg versus omeprazole (ome) 20 mg in patients with mild gastroesophageal reflux disease. Gastroenterology 1999, 116: A118.
158. Bardhan, K.D. The role of proton pump inhibitors in the treatment of gastroesophageal reflux disease. Aliment Pharmacol Ther 1995, 2 (Suppl. 1): 15-25.
159. Chiba, N., de Gara, C.J., Wilkinson, J., Hunt, R.H. Rate of healing and heartburn relief in grade 2-4 gastroesophageal reflux disease: A meta-analysis by drug class. Gastroenterology 1997, 112: A10.
160. Holtmann, G., Cain, C.R., Malfertheiner, P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999, 117: 11-6.
161. Hazenberg, B.P., Geraedtz, A.A.M., de Groot, G.H. Omeprazole versus ranitidine in the treatment of symptomatic mild reflux oesophagitis. A Dutch multicentre study. Gut 1994. 35 (Suppl. 2): W26.
162. Bergmann, J.F., Hamelin, B., Barbier, J.P. Comparison of the cost-efficacy ratio of omeprazole and ranitidine in the treatment of reflux esophagitis. Gastroenterol Clin Biol 1995, 19: 482-6.
163. Corinaldesi, R., Valentini, M., Belaïche, J., Colin, R., Geldof, H., Maier, C. Pantoprazole and omeprazole in the treatment of reflux oesophagitis: A European multicentre study. The European Pantoprazole Study Group. Aliment Pharmacol Ther 1995, 9: 667-71.
164. Mössner, J., Hölscher, A.H., Herz, F., Schneider, A. A double-blind study of pantoprazole and omeprazole in the treatment of reflux esophagitis: A multicentre trial. Aliment Pharmacol Ther 1995, 9: 321-6.
165. Hotz, J., Gangl, A., Heinzerling, H. Pantoprazole vs omeprazole in acute reflux esophagitis. Gastroenterology 1996, 110: A136.
166. Dupas, J.L., Houke, P., Giret-d'Orsay, G., Samoyeau, R. First comparison of pantoprazole versus lansoprazole in hospital and private practice patients with reflux esophagitis. Gastroenterology 1998, 114: A110.
167. Vicari, F., Belin, J., Marek, L. Pantoprazole 40 mg versus omeprazole 20 mg in the treatment of reflux oesophagitis: Results of a French multicentric double-blind comparative trial. Gastroenterology 1998, 114: A324.
168. van Rensburg, C.J., Honiball, P.J., Grundling, H.D. et al. Efficacy and tolerability of pantoprazole 40 mg versus 80 mg in patients with reflux
169. Wurzer, H., Schütze, K., Bethke, T., Fischer, R., Lühmann, F., Riesenhuber, C. Efficacy and safety of pantoprazole in patients with gastroesophageal reflux disease using an intravenous-oral regimen. Austrian Intravenous Pantoprazole Study Group. Hepatogastroenterology 1999, 46: 1809-15.
170. Fumagalli, I., Klein, M., Fischer, R. Comparison of intravenous with oral pantoprazole in symptom relief and healing of reflux esophagitis. Gastroenterology 1998, 114: A126.
171. Mössner, J., Koop, H., Porst, H., Wübbolding, H., Schneider, A., Maier, C. One-year prophylactic efficacy and safety of pantoprazole in controlling gastro-oesophageal reflux symptoms in patients with healed reflux oesophagitis. Aliment Pharmacol Ther 1997, 11: 1087-92.
172. Escourrou, J., Deprez, P., Saggioro, H. et al. Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux oesophagitis. Aliment Pharmacol Ther 1999, 13: 1481-91.
173. Plein, K., Hotz, J., Wurzer, H., Fumagalli, I., Lühmann, R., Schneider, A. Pantoprazole 20 mg is an effective maintenance therapy for patients with gastroesophageal reflux disease. Eur J Gastroenterol Hepatol 1999, in press.
174. van Rensburg, C.J., Honiball, P.J., van Zyl, J.H. et al. Safety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux oesophagitis - A 2-year follow-up. Aliment Pharmacol Ther 1999, 13: 1023-8.
175. Hungin, P. Patients with symptomatic reflux disease in general practice. Clinical presentation and endoscopic findings. Gut 1991, 32: A17.
176. Murdoch, R.H., Pappa, K.A., Giefer, E.E., Payne, J.E., Sanders, M., Sirgo, M.A. Endoscopic findings in a target population for over the counter treatment of heartburn. Gastroenterology 1994, 106: A146.
177. Venables, T., Newland, R., Patel, A.C. et al. A comparison of omeprazole 10 mg and 20 mg with ranitidine 150 mg bd for the treatment of GERD in primary care. Gut 1995, 37 (Suppl. 2): A45.
178. Farup, P.G., Modalsi, B., Tholfsen, J.K., Efskind, P.S., Kildebo, S., Lunde, O.C. Ranitidine 300 mg once after dilatation of peptic oesophageal strictures. A one year placebo controlled follow up study. Gastroenterology 1992, 102: A66.
179. 2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology 1994, 106: 907-15.
180. Swarbrick, E.T., Gough, A.L., Christian, J., Langworthy, H. Prevention of recurrence esophageal stricture: A comparative study of lansoprazole and high dose ranitidine. Gastroenterology 1994, 106: A189.
181. Jasperson, D., Diehl, K.L., Schoeppner, H., Geyer, P., Martens, E. A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis. Aliment Pharmacol Ther 1998, 12: 49-52.
182. Carlsson, R., Bate, C., Dent, J. et al. Does H. pylori infection influence the response to treatment with acid inhibition in patients with gastroesophageal reflux disease? Scand J Gastroenterol 1997, 32 (Suppl. 124): F70.
183. Plein, K., Hotz, J., Fischer, R., Schneider, A. Clinical efficacy and safety of an intravenous (i.v.) pantoprazole formulation in erosive reflux esophagitis. The German Intravenous Pantoprazole Study Group. Gastroenterology 1997, 112: A260.
184. Gut, A., Bründler, R., Gaia, C., Netzer, P., Halter, F., Inauen, W. Reduction of oesophageal bile-and acid-reflux by pantoprazole in patients with reflux oesophagitis. Gut 1997, 41: A202.
185. Kauer, W.K., Peters, J.H., Demeester, T.R., Ireland, A.P., Bremmer, C.G., Hagan, J.A. Mixed reflux of gastric and duodenal juices is more harmful to the oesophagus than gastric juice alone. Ann Surg 1995, 222: 525-33.
186. Vaezi, M., Richter, J.E. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 1996, 111: 1192-9.
187. Neville, P.M., Moayyedi, P., Edwards, A., Axon, A.T.R. Response to pantoprazole is an effective diagnostic test for gastroesophageal reflux disease: Results of a randomized double-blind placebo-controlled pilot study. Gastroenterology 1998, 114: A242.
188. Klauser, A.G., Schindlbeck, N.E., Müller-Lissner, S.A. Symptoms in gastro-oesophageal reflux disease. Lancet 1990, 335: 205-8.
189. Kuipers, E.J., Klinkenberg Knol, E.C., Jansen, E.H. et al. Omeprazole as a diagnostic tool in reflux disease. Gastroenterology 1995, 108: A137.
190. Brunner, G., Creutzfeldt, W., Harke, U., Lamberts, R. Therapy with omeprazole in patients with peptic ulcerations resistant to extended high dose ranitidine treatment. Digestion 1988, 38: 80-90.
191. Brunner, G., Harke, U. Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. Aliment Pharmacol Ther 1994, 8 (Suppl. 1): 59-64.
192. Lamberts, R., Cruetzfeldt, W., Struber, H.G., Brunner, G., Solcia, E. Long term omperazole therapy in peptic ulcer disease: Gastrin, endocrine cell growth and gastritis. Gastroenterology 1993, 104: 1356-70.
193. Bardhan, K.D., Cherian, P., Polak, J.M., Perry, M., Jones, R.B., Bishop, A. Pantoprazole in aggressive refractory acid-peptic disease. Gastroenterology 1996, 110: A57.
194. Müller, P., Simon, B. The action of the proton pump inhibitor pantoprazole against acetylsalicylic acid-induced gastroduodenopathy in comparison to ranitidine. An endoscopic controlled double-blind comparison. Arzneim-Forsch/Drug Res 1998, 48: 482-5.
195. Bianchi Porro, G., Imbesi, V., Lazzaroni, M., Montrone, F., Santagada, T. Pantoprazole vs placebo in prevention of NSAID-induced ulcers. Gastroenterology 1998, 114: A74.
196. Yeomans, N.D., Tulassay, Z., Juhdsz, L. et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-Associated Ulcer Treatment (ASTRONAUT) Study Group. New Engl J Med 1998, 338: 719-26.
197. Hawkey, C.J., Swannell, A.J., Eriksson, S. et al. Lower frequency of gastroduodenal ulcers and erosion and dyspeptic symptoms in NSAID users during maintenance with omeprazole compared to ranitidine. Gastroenterology 1996, 110: A131.
198. Hawkey, C.J., Karrasch, J.A., Szczepafiski, L. et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-Induced Ulcer Management (OMNIUM) Study Group. New Engl J Med 1998, 338: 727-34.
199. Wiklund, I., Swannell, A.J., Yeomans, N.D., Langstrom, G., Naesdal, J., Hawkey. C.J. Quality of life in patients with non-steroidal anti-inflammatory drug associated gastroduodenal lesions during healing and maintenance: A randomised comparison of omeprazole and misoprostol. Gut 1996, 39 (Suppl. 3): A843.
200. Hawkey, C.J., Swanell, A.J., Yeomans, N.D., Langstrom, G., Lofberg, I., Taure, E. Site specific ulcer relapse in non-steroidal anti-inflammatory drug users: Improved prognosis with H. pylori and with omeprazole compared to misoprostol. Gut 1996, 39 (Suppl. 3): A149.
201. Agrawal, N., Safdi, M., Wruble, L., Karvois, D., Greski-Rose, P. Effectiveness of lansoprazole in the healing of NSAID-induced gastric ulcer in patients continuing to take NSAIDs. Gastroenterology 1998, 114: A52.
202. Radebold, K., Bornman, P.C., van Wyk, M.E.C., Marks, I.N., Terblanche, J. Preliminary results of the proton-pump inhibitor pantoprazole in patients with Zollinger-Ellison syndrome. Gastroenterology 1997, 112: A37.
203. Jensen, R.T. Gastrointestinal endocrine tumours, gastrinoma. Bailliers Clin Gastroenterol 1996, 10: 603-43.
204. Scholten, T., Hahn, E.G., Bosseckert, H., Von Kleist, D.H., Dammann, H.G. Clinical tolerability of pantoprazole compared with ranitidine and famotidine. International Clinical Practice Series. The German Phase IV Pantoprazole Programme. Domschke, W. (Ed.). Wells Medical Ltd.: Kent 1997, 31-6.
205. Hahn, E.G., Bosseckert, H., Dammann, H.G., Schlander, M. Tolerability and safety profile of pantoprazole based on 100,134 patients: Results of a German post marketing surveillance programme. Gastroenterology 1997, 112: A138.
206. Arnold, R. Safety of proton pump inhibitors, an overview. Aliment Pharmacol Ther 1994, 8 (Suppl. 1): 65-70.
207. Athmann, C., Mander, I., Brunner, G. et al. Histology and safety parameters during long-term maintenance with pantoprazole in severe acid-peptic disease. Gastroenterology 1998, 114: A60.
208. Bishop, A., Romanska, H., Polak, J. et al. Effect of long-term maintenance with pantoprazole on serum gastrin and histology parameters in severe acid-peptic disease. Gastroenteroloay 1998, 114: A75.
209. Viergutz, S., Culshaw, K., Schandler, M. A comparison of the cost effectiveness of pantoprazole in treating peptic ulcer disease in 6 European countries. Gastroenterology 1998, 114: A324.